Sleep Number Announces First Quarter 2026 Results

Sleep Number Corporation (Nasdaq: SNBR) today reported results for the quarter ended April 4, 2026.

Linda Findley, President and CEO, commented, “Q1 came in as expected given the soft start to the year, but year-over-year demand improved steadily throughout the quarter, ending with growth in March over last year. We are confident in the early positive metrics we are seeing from our new product launch and marketing campaigns, and the customer feedback on our new beds is fantastic. We believe this, combined with the full realization of our cost savings actions, puts us in line with the financial indications we highlighted in the previous earnings call.

“With the additional short-term liquidity provided by our existing lender group, we are fully focused on securing a long-term capital solution and are moving through the process of evaluating a range of strategic and financing options to maximize stakeholder value. I’m proud of the significant progress the team has made on the turnaround, and I believe we have positioned Sleep Number well for future growth.”

First Quarter Overview (all comparisons year-over-year unless otherwise noted)

  • Net sales of $319 million were down 18.9%, driven by lower volume and a reduced store count.

  • Gross profit was $185 million, a decrease of $56 million. Gross profit margin of 57.9% compared to 61.2% for the same period last year, primarily driven by a shift in mix to the new ComfortMode bed and discounting of legacy inventory.

  • Operating expenses were $221 million. Adjusted operating expenses before restructuring and other non-recurring costs were $195 million, a decrease of $42 million, or 18%, driven by lower marketing and selling expenses, general and administrative expenses, and research and development expenses.

  • Restructuring and other non-recurring costs in the quarter were $22 million, primarily driven by store and office closure costs, strategic alternative legal and advisory fees, other professional and bank fees and severance related expenses.

  • Net loss was $50 million, compared to a net loss of $9 million for the same period last year, driven primarily by lower net sales, partially offset by lower operating expenses.

  • Adjusted EBITDA was $6 million, down 74%, driven by a decline in net sales and associated loss of fixed cost leverage, partially offset by lower operating expenses. Adjusted EBITDA margin of 1.8%, down 380 basis points (“bps”).

Cash Flows, Liquidity and Balance Sheet Highlights (all comparisons year-over-year unless otherwise noted)

  • Net cash used in year-to-date operating activities was $8 million, down $5 million.

  • Year-to-date Free cash flow was a use of $13.2 million.

Additional Business Highlights

Sleep Number is executing a turnaround strategy centered on product, marketing and distribution with ongoing cost savings and operating efficiencies to reignite growth and increase financial resilience. Recent highlights include:

  • Product Portfolio Transformation – Completed the largest product redesign in nearly a decade, and all stores are fully reset. Early customer response has been encouraging, with initial indicators showing improved product engagement, strong attachment to the ComfortNext portfolio, and a simplified shopping experience across stores and digital channels.

  • Modernized Marketing Foundation – Launched “To a Good Life’s Sleep™,” the company’s first major integrated campaign in several years and the next phase of its brand evolution. The campaign supports the redesigned portfolio with benefit-led messaging focused on personalized, adjustable comfort that adapts as customers’ needs change.

  • Cost Structure Reset – Continued to right-size the fixed cost base, with approximately $200 million of annualized cost savings already executed, including efficiencies across G&A, corporate structure, technology, and real estate.

  • Capital Structure Review – Reached an agreement with existing lenders that provides relief from certain financial covenants and adds $55 million of incremental liquidity, including a new $25 million term loan as detailed in the company’s prior press release and Form 8-K filed on April 28, 2026. The agreement provides additional stability and flexibility to continue executing the turnaround while the company works with advisors to evaluate strategic and financing options for a longer-term capital structure solution.

Financial Outlook

In connection with the company’s previously announced engagement of Guggenheim Securities to evaluate strategic and financing options, the company is not providing financial guidance. The company, however, expects performance to be consistent with the financial indications it provided on the 2025 fourth quarter and full year earnings call. The company does not intend to provide forward-looking financial guidance while the strategic process is ongoing.

Conference Call Information

Management will host its regularly scheduled conference call to discuss the company’s results at 8:30 a.m. ET (7:30 a.m. CT; 5:30 a.m. PT) today. To access the webcast, please visit the investor relations area of the Sleep Number website at https://ir.sleepnumber.com. The webcast replay will remain available for approximately 60 days.

About Sleep Number Corporation

Sleep Number® is the leader in personalized sleep wellness. Its mattresses are designed to evolve with each sleeper to help them feel and perform their best. With adjustable firmness, pressure-relieving support and temperature balancing comfort built into every mattress, Sleep Number beds adapt to customers’ changing needs, night after night, year after year.

Backed by almost 40 years of innovation, 1,000+ patents and patents pending, and billions of hours of sleep data, Sleep Number has helped more than 16 million people achieve their best sleep. The fully integrated model ensures quality, durability, and care at every step—from design and craftsmanship to delivery and long-term support.

Sleep Number products are awarded the industry’s top recognitions, including ranked #1 in customer satisfaction for mattresses purchased in-store and online, and #1 in comfort, by J.D. Power. In addition, the company is the Official Sleep + Wellness Partner of the NFL, marking a relationship that leverages players, team partnerships, and league-wide initiatives to amplify brand awareness and drive consumer engagement.

Sleep Number mattresses, bases, bedding, and furniture are available exclusively at its over 570 stores nationwide and online. To learn more, visit SleepNumber.com or a store near you.

Forward-looking Statements

Statements used in this news release relating to future plans, events, financial results or performance, such as the statements about the company’s ability to: advance and execute its turnaround to drive growth and increase financial resilience; achieve and fully realize cost savings and operational efficiencies; perform in line with its financial indications highlighted in the previous earnings call; successfully evaluate and execute strategic and financing options to achieve a long-term capital structure solution to maximize value; and realize the expected benefits from its new product portfolio and marketing initiatives are forward-looking statements subject to certain risks and uncertainties which could cause the company’s results to differ materially, including its ability to continue as a going concern as detailed in the company’s Annual Report on Form 10-K for fiscal year 2025 and its Quarterly Report on Form 10-Q for the first quarter of fiscal 2026 and secure a long-term capital solution through an evaluation of strategic and financing options. The most important risks and uncertainties are described in the company’s filings with the Securities and Exchange Commission, including in Item 1A of the company’s Annual Report on Form 10-K and other periodic reports. Forward-looking statements speak only as of the date they are made, and the company does not undertake any obligation to update any forward-looking statement.

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Consolidated Statements of Operations

(unaudited – in thousands, except per share amounts)

 

 

Three Months Ended

 

April 4,

2026

 

% of

Net Sales

 

March 29,

2025

 

% of

Net Sales

Net sales

$

318,987

 

 

100.0

%

 

$

393,261

 

 

100.0

%

Cost of sales

 

134,372

 

 

42.1

%

 

 

152,726

 

 

38.8

%

Gross profit

 

184,615

 

 

57.9

%

 

 

240,535

 

 

61.2

%

Operating expenses:

 

 

 

 

 

 

 

Sales and marketing

 

160,795

 

 

50.4

%

 

 

189,103

 

 

48.1

%

General and administrative

 

33,592

 

 

10.5

%

 

 

38,619

 

 

9.8

%

Research and development

 

5,348

 

 

1.7

%

 

 

10,903

 

 

2.8

%

Restructuring costs

 

21,736

 

 

6.8

%

 

 

60

 

 

0.0

%

Total operating expenses

 

221,471

 

 

69.4

%

 

 

238,685

 

 

60.7

%

Operating (loss) income

 

(36,856

)

 

(11.6

%)

 

 

1,850

 

 

0.5

%

Interest expense, net

 

13,103

 

 

4.1

%

 

 

11,081

 

 

2.8

%

Loss before income taxes

 

(49,959

)

 

(15.7

%)

 

 

(9,231

)

 

(2.3

%)

Income tax expense (benefit)

 

338

 

 

0.1

%

 

 

(585

)

 

(0.1

%)

Net loss

$

(50,297

)

 

(15.8

%)

 

$

(8,646

)

 

(2.2

%)

 

 

 

 

 

 

 

 

Net loss per share – basic and diluted

$

(2.19

)

 

 

 

$

(0.38

)

 

 

 

 

 

 

 

 

 

 

Reconciliation of weighted-average shares outstanding:

Basic weighted-average shares outstanding

 

22,991

 

 

 

 

 

22,706

 

 

 

Dilutive effect of stock-based awards

 

 

 

 

 

 

 

 

 

Diluted weighted-average shares outstanding

 

22,991

 

 

 

 

 

22,706

 

 

 

 

For the three months ended April 4, 2026 and March 29, 2025, potentially dilutive stock-based awards have been excluded from the calculation of diluted weighted-average shares outstanding, as their inclusion would have had an anti-dilutive effect on our net loss per diluted share.

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Consolidated Balance Sheets

(unaudited – in thousands, except per share amounts)

subject to reclassification

 

 

April 4,

2026

 

January 3,

2026

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

1,484

 

 

$

1,693

 

Accounts receivable, net of allowances of $656 and $694, respectively

 

13,354

 

 

 

15,502

 

Inventories

 

78,216

 

 

 

82,233

 

Prepaid expenses

 

19,727

 

 

 

13,656

 

Other current assets

 

30,694

 

 

 

36,873

 

Total current assets

 

143,475

 

 

 

149,957

 

Non-current assets:

 

 

 

Property and equipment, net

 

73,755

 

 

 

86,528

 

Operating lease right-of-use assets

 

295,315

 

 

 

311,723

 

Goodwill and intangible assets, net

 

66,131

 

 

 

66,186

 

Deferred income taxes

 

399

 

 

 

399

 

Other non-current assets

 

61,933

 

 

 

65,267

 

Total assets

$

641,008

 

 

$

680,060

 

Liabilities and Shareholders’ Deficit

 

 

 

Current liabilities:

 

 

 

Borrowings under credit facility

$

605,600

 

 

$

588,200

 

Accounts payable

 

116,395

 

 

 

117,977

 

Customer prepayments

 

43,338

 

 

 

39,527

 

Accrued sales returns

 

12,266

 

 

 

12,817

 

Compensation and benefits

 

19,415

 

 

 

14,975

 

Taxes and withholding

 

10,908

 

 

 

11,429

 

Operating lease liabilities

 

79,340

 

 

 

81,191

 

Other current liabilities

 

44,447

 

 

 

46,430

 

Total current liabilities

 

931,709

 

 

 

912,546

 

Non-current liabilities:

 

 

 

Operating lease liabilities

 

268,697

 

 

 

273,111

 

Other non-current liabilities

 

66,921

 

 

 

72,878

 

Total liabilities

 

1,267,327

 

 

 

1,258,535

 

Shareholders’ deficit:

 

 

 

Undesignated preferred stock; 5,000 shares authorized, no shares issued and outstanding

 

 

 

 

 

Common stock, $0.01 par value; 142,500 shares authorized, 23,049 and 22,860 shares issued and outstanding, respectively

 

230

 

 

 

229

 

Additional paid-in capital

 

34,906

 

 

 

32,454

 

Accumulated deficit

 

(661,455

)

 

 

(611,158

)

Total shareholders’ deficit

 

(626,319

)

 

 

(578,475

)

Total liabilities and shareholders’ deficit

$

641,008

 

 

$

680,060

 

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(unaudited – in thousands)

subject to reclassification

 

 

Three Months Ended

 

April 4,

2026

 

March 29,

2025

Cash flows from operating activities:

 

 

 

Net loss

$

(50,297

)

 

$

(8,646

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

Depreciation and amortization

 

12,371

 

 

 

14,836

 

Stock-based compensation

 

2,826

 

 

 

3,951

 

Inventory obsolescence write off

 

2,099

 

 

 

 

Loss on disposal and impairment of leased assets

 

17,539

 

 

 

17

 

Deferred income taxes

 

 

 

 

(1,321

)

Changes in operating assets and liabilities:

 

 

 

Accounts receivable

 

2,148

 

 

 

3,291

 

Inventories

 

1,918

 

 

 

(724

)

Income taxes

 

482

 

 

 

736

 

Prepaid expenses and other assets

 

(4,266

)

 

 

781

 

Accounts payable

 

3,818

 

 

 

8,784

 

Customer prepayments

 

3,811

 

 

 

(6,576

)

Accrued compensation and benefits

 

4,354

 

 

 

(9,686

)

Other taxes and withholding

 

(1,003

)

 

 

(1,925

)

Other accruals and liabilities

 

(3,551

)

 

 

(6,144

)

Net cash used in operating activities

 

(7,751

)

 

 

(2,626

)

 

 

 

 

Cash flows from investing activities:

 

 

 

Purchases of property and equipment

 

(5,441

)

 

 

(4,599

)

Net cash used in investing activities

 

(5,441

)

 

 

(4,599

)

 

 

 

 

Cash flows from financing activities:

 

 

 

Net increase in short-term borrowings

 

13,805

 

 

 

9,087

 

Repurchases of common stock

 

(373

)

 

 

(563

)

Debt issuance costs

 

(449

)

 

 

(1,558

)

Net cash provided by financing activities

 

12,983

 

 

 

6,966

 

 

 

 

 

Net decrease in cash and cash equivalents

 

(209

)

 

 

(259

)

Cash and cash equivalents, at beginning of period

 

1,693

 

 

 

1,950

 

Cash and cash equivalents, at end of period

$

1,484

 

 

$

1,691

 

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Supplemental Financial Information

(unaudited)

 

 

Three Months Ended

 

April 4,

2026

 

March 29,

2025

Percent of sales:

 

 

 

Retail stores

 

87.0

%

 

 

87.6

%

Online, phone, chat and other

 

13.0

%

 

 

12.4

%

Total Company

 

100.0

%

 

 

100.0

%

 

 

 

 

Sales change rates:

 

 

 

Retail comparable-store sales

 

(17

%)

 

 

(15

%)

Online, phone and chat

 

(15

%)

 

 

(12

%)

Total Retail comparable sales change

 

(16

%)

 

 

(15

%)

Net opened/closed stores and other

 

(3

%)

 

 

(1

%)

Total Company

 

(19

%)

 

 

(16

%)

 

 

 

 

Stores open:

 

 

 

Beginning of period

 

600

 

 

 

640

 

Opened

 

 

 

 

2

 

Closed

 

(23

)

 

 

(5

)

End of period

 

577

 

 

 

637

 

 

 

 

 

Other metrics:

 

 

 

Average sales per store ($ in 000’s)1

$

2,170

 

 

$

2,495

 

Average sales per square foot1

$

700

 

 

$

807

 

Stores > $2 million net sales2

 

31

%

 

 

51

%

Stores > $3 million net sales2

 

6

%

 

 

15

%

Average revenue per mattress unit3

$

6,021

 

 

$

5,992

 

1

Trailing twelve months Total Retail comparable sales per store open at least one year.

2

Trailing twelve months for stores open at least one year (excludes online, phone and chat sales).

3

Represents Total Retail net sales divided by Total Retail mattress units.

SLEEP NUMBER CORPORATION AND SUBSIDIARIES

Earnings before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA)

(in thousands)

 

We define earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA) as net loss plus: income tax expense (benefit), interest expense, depreciation and amortization, stock-based compensation, restructuring costs, other non-recurring items, and asset impairments. Management believes Adjusted EBITDA is a useful indicator of our financial performance and our ability to generate cash from operating activities. Our definition of Adjusted EBITDA may not be comparable to similarly titled definitions used by other companies. The table below reconciles Adjusted EBITDA, which is a non-GAAP financial measure, to the comparable GAAP financial measure:

 

 

Three Months Ended

 

Trailing Twelve Months Ended

 

April 4,

2026

 

March 29,

2025

 

April 4,

2026

 

March 29,

2025

Net loss

$

(50,297

)

 

$

(8,646

)

 

$

(173,609

)

 

$

(21,498

)

Income tax expense (benefit)

 

338

 

 

 

(585

)

 

 

36,907

 

 

 

(6,472

)

Interest expense

 

13,103

 

 

 

11,081

 

 

 

51,404

 

 

 

47,150

 

Depreciation and amortization

 

11,126

 

 

 

14,406

 

 

 

49,889

 

 

 

62,240

 

Stock-based compensation

 

2,827

 

 

 

3,951

 

 

 

5,158

 

 

 

11,278

 

Restructuring costs1

 

21,736

 

 

 

60

 

 

 

72,373

 

 

 

7,526

 

Other non-recurring items2

 

6,917

 

 

 

1,774

 

 

 

19,841

 

 

 

2,772

 

Asset impairments

 

 

 

 

 

 

 

 

 

 

1,220

 

Adjusted EBITDA

$

5,750

 

 

$

22,041

 

 

$

61,963

 

 

$

104,216

 

1

Represents costs related to business restructuring actions.

2

Non‑recurring costs represent discrete, non‑operational items, including obsolete inventory associated with the Company’s product transition, strategic alternative legal and advisory fees, executive transition and search fees, proxy contest costs, public debt issuance cost write-off, tax matters and other non‑routine professional and bank fees. These amounts are treated as permitted add-backs in the calculation of Adjusted EBITDA in accordance with the Company’s Credit Agreement.

Free Cash Flow

(in thousands)

 

 

Three Months Ended

 

Trailing Twelve Months Ended

 

April 4,

2026

 

March 29,

2025

 

April 4,

2026

 

March 29,

2025

Net cash used in operating activities

$

(7,751

)

 

$

(2,626

)

 

$

(8,408

)

 

$

(9,228

)

Subtract: Purchases of property and equipment

 

5,441

 

 

 

4,599

 

 

 

15,249

 

 

 

18,796

 

Free cash flow

$

(13,192

)

 

$

(7,225

)

 

$

(23,657

)

 

$

(28,024

)

Reconciliation of GAAP to Non-GAAP Financial Measures

(in thousands)

 

 

Three Months Ended

 

April 4,

2026

 

March 29,

2025

Operating expenses

$

221,471

 

$

238,685

Subtract: Restructuring costs

 

21,736

 

 

60

Subtract: Other non-recurring items1

 

4,818

 

 

1,774

Non-GAAP operating expenses

$

194,917

 

$

236,851

Adjusted operating expense reduction versus prior period, excluding restructuring costs and non-recurring items

$

41,934

 

 

 

1 Excludes inventory obsolescence write off of $2.1 million recorded in the three months ended April 4, 2026, which is included in the cost of sales line on the consolidated statement of operations.

 

Note – Our Adjusted EBITDA, Free Cash Flow and Adjusted Operating Expenses are considered non-GAAP financial measures and are not in accordance with, or preferable to, “as reported,” or GAAP financial data. However, we are providing this information as we believe it facilitates analysis of the Company’s financial performance by investors and financial analysts.

 

GAAP – generally accepted accounting principles in the U.S.

SLEEP NUMBER CORPORATION AND SUBSIDIARIES

Calculation of Return on Invested Capital (Adjusted ROIC)

(in thousands)

 

Adjusted ROIC is a financial measure we use to determine how efficiently we deploy our capital. It quantifies the return we earn on our adjusted invested capital. Management believes Adjusted ROIC is also a useful metric for investors and financial analysts. We compute Adjusted ROIC as outlined below. Our definition and calculation of Adjusted ROIC may not be comparable to similarly titled definitions and calculations used by other companies. The tables below reconcile adjusted net operating profit after taxes (Adjusted NOPAT) and total adjusted invested capital, which are non-GAAP financial measures, to the comparable GAAP financial measures:

 

 

Trailing Twelve Months Ended

 

April 4,

2026

 

March 29,

2025

Adjusted net operating profit after taxes (Adjusted NOPAT)

 

 

 

Operating (loss) income

$

(85,299

)

 

$

19,180

 

Add: Operating lease interest1

 

23,832

 

 

 

26,098

 

Less: Income taxes2

 

7,902

 

 

 

(10,022

)

Adjusted NOPAT

$

(53,565

)

 

$

35,256

 

 

 

 

 

Average adjusted invested capital

 

 

 

Total deficit

$

(626,317

)

 

$

(456,844

)

Add: Long-term debt3

 

605,720

 

 

 

557,921

 

Add: Operating lease liabilities4

 

348,037

 

 

 

376,909

 

Total adjusted invested capital at end of period

$

327,440

 

 

$

477,986

 

 

 

 

 

Average adjusted invested capital5

$

408,437

 

 

$

487,361

 

 

 

 

 

Adjusted ROIC6

 

(13.1

%)

 

 

7.2

%

1

Represents the interest expense component of lease expense included in our financial statements under ASC 842, Leases.

2

Reflects annual effective income tax rates, before discrete adjustments, of 12.9% and 22.1% for April 4, 2026 and March 29, 2025, respectively.

3

Long-term debt includes existing finance lease liabilities.

4

Reflects operating lease liabilities included in our financial statements under ASC 842.

5

Average adjusted invested capital represents the average of the last five fiscal quarters’ ending adjusted invested capital balances.

6

Adjusted ROIC equals Adjusted NOPAT divided by average adjusted invested capital.

 

 

Note – The Company’s Adjusted ROIC calculation and data are considered non-GAAP financial measures and are not in accordance with, or preferable to, “as reported,” or GAAP financial data. However, we are providing this information as we believe it facilitates analysis of the Company’s financial performance by investors and financial analysts.

GAAP – generally accepted accounting principles in the U.S.

 

Media gallery